BioCentury
ARTICLE | Clinical News

Faster-acting insulin aspart: Phase IIIa data

August 1, 2016 7:00 AM UTC

Top-line data from the double-blind, international Phase IIIa onset 1 trial in 1,143 Type I diabetics showed that subcutaneous FIAsp dosed at mealtime plus basal insulin met the primary endpoint of re...